Picture Kentro Design Is Key to Your Success Berlin 650x100px
Collaboration › Details

AstraZeneca–Quell Therapeutics: T cell therapy, 202306– collab developm $85m incl equity investment + >$2b milstones + royalties Tregs for T1D + IBD


Period Period 2023-06-09
Organisations Partner, 1st AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Partner, 2nd Quell Therapeutics Ltd. (QuellTX)
Product Product  Foxp3 Phenotype Lock (Quell Therapeutics)
Index term Index term Quell Therapeutics–AstraZeneca: Investment, 202306 equity investment €na by AstraZeneca as part of collaboration
Person Person Pangalos, Menelas (AstraZeneca 201303 EVP Innovative Medicines + Early Development Biotech Unit)

Quell Therapeutics Ltd.. (6/9/23). "Press Release: Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases". London

> Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial capabilities as well as its deep therapeutic area knowledge

> Collaboration focused on two autoimmune disease areas – Type 1 Diabetes and Inflammatory Bowel Disease

> Quell will receive $85 million upfront and is eligible to receive over $2 billion for further development and commercialization milestones, if successful, plus tiered royalties

Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that it has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell therapies for two autoimmune disease indications.

“We are extremely pleased to have AstraZeneca on board as our first major partner. This collaboration builds on our pioneering work to develop exquisitely engineered, multi-modular Treg cell therapies for immune disorders and provides excellent validation for the technologies and capabilities we have established,” said Iain McGill, Chief Executive Officer of Quell Therapeutics. “We are proud and incredibly excited to partner our leading science with the deep experience of AstraZeneca to accelerate the application of our Treg cell therapy platform in major autoimmune disease, where we believe there is a broad opportunity to reset immune tolerance and drive durable responses for patients.”

“This is a very exciting collaboration with Quell as we look to expand our next-generation therapeutic toolbox and explore the untapped potential with Treg cell therapies in autoimmune indications. This is aligned with our strategy to target underlying disease drivers, stop or slow disease progression and ultimately accelerate the delivery of transformative care to patients with chronic autoimmune conditions,” added Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca.

Under the terms of the agreement, Quell’s proprietary toolbox of Treg cell engineering modules, including its Foxp3 Phenotype Lock, will be leveraged to develop autologous multi-modular Treg cell therapy candidates for Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD). AstraZeneca will have the option to further develop and commercialize successful candidates, with Quell responsible for the process development and manufacturing of clinical candidates through to the end of the first-in-human clinical study.

Quell will receive $85 million upfront from AstraZeneca, which comprises a predominant cash payment and an equity investment. Quell is also eligible to receive over $2 billion for further development and commercialization milestones, if successful, plus tiered royalties. In addition, Quell retains an option, which can be exercised either after approval of an Investigational New Drug (IND) application or at the end of the Phase I/II clinical study, to co-develop Treg cell therapies from the T1D program with AstraZeneca in the United States in exchange for additional milestone payments and increased royalties on US net sales.

Quell retains full ownership of its lead Treg cell therapy candidate QEL-001, which is designed to prevent organ rejection and eliminate the need for lifelong immunosuppression in liver transplant patients and is expected to enter first-in-human trials during 2023, as well as its preclinical program in neuroinflammation.

– Ends –

About Quell Therapeutics

Quell Therapeutics is a world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.

The Company is leveraging its proprietary Foxp3 Phenotype Lock technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency and stability than earlier generations of Treg cell therapy approaches.

Quell’s lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases.


Luke Henry, Chief Business Officer
Quell Therapeutics

Media: Mark Swallow, Frazer Hall, Sandi Greenwood, Eleanor Perkin
MEDiSTRAVA Consulting
+44 (0) 203 928 6900

Investors: Christina Tartaglia
Stern Investor Relations, Inc.
+1 212 362 1200

Record changed: 2023-06-11


Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top